GUSTO IV ACS: Trial Design
GUSTO IV ACS: Trial Design. Abciximab versus placebo in very high-risk patients with non-ST elevation acute coronary syndromes: ST ¯ > 0.5 mm or elevated troponin I Medical management for at least 60 hours If a patient underwent PCI within 30 days, abciximab permitted in all patients
138 views • 7 slides